Keywords: fda, advisers, mull, requirements, topical, corticosteroids, otc
FDA advisers mull requirements for topical corticosteroids OTC switch
Article | 11 April 2005
Pharmaceutical manufacturers would need to show that their products cause only minimal suppression of the hypothalamic-pituitary-adrenal (HPA) axis if they ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
